Ivonescimab trial data shows survival gains in lung cancer patients

A Phase 3 trial conducted in China reveals that the experimental drug ivonescimab, when paired with chemotherapy, reduced the risk of death by 34% in patients with squamous non-small-cell lung cancer. The results, showing a four-month median survival advantage, have intensified global interest in the bispecific antibody’s potential market impact.

The data, presented by developers Akeso and Summit Therapeutics, suggests the drug outperforms current standard combinations of immunotherapy and chemotherapy. By targeting both PD-1 and VEGF pathways, ivonescimab occupies a unique position in oncology, drawing comparisons to blockbusters like Merck’s Keytruda and Roche’s Avastin. While the clinical results are statistically significant, the medical community remains cautious. Dr. Suresh Ramalingam of the Winship Cancer Institute noted that while survival improvements in difficult-to-treat populations are encouraging, the trial’s exclusive focus on Chinese patients leaves open questions regarding its efficacy across broader, global demographics.

These uncertainties have fueled a volatile market response for Summit Therapeutics. Shares surged nearly 600% over the last two years following earlier reports that the drug controlled tumors more effectively than Keytruda in localized testing. However, the stock has faced downward pressure in recent weeks as investors grapple with the possibility that the clinical benefits might not translate outside of the initial study group. A global Phase 3 study is currently underway to address these concerns and determine if the drug will truly succeed as a successor to current standard-of-care treatments or face the same limitations as previous experimental immune therapies.